Severe systemic vasculitis induced by ibrutinib
The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib. A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecroti...
Gespeichert in:
| Veröffentlicht in: | La revue de medecine interne 2024-01, Vol.45 (1), p.13-16 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | La revue de medecine interne |
| container_volume | 45 |
| creator | Fenot, M Woaye Hune, P Vigouroux, S Veyrac, G Poiraud, C |
| description | The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib.
A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecrotic lesions on toes and tongue occurred. Skin biopsy found vasculitis of small and medium vessels. Biologic tests were negative. This vasculitis was refractory to systemic corticosteroid therapy and azathioprine. Ibrutinib was stopped on the hypothesis of drug-induced vasculitis. Skin lesions improved after discontinuation of ibrutinib.
The mechanism of action of ibrutinib does not explain the occurrence of vasculitis and an immunoallergic mechanism is suspected. |
| doi_str_mv | 10.1016/j.revmed.2023.10.448 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2889240131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2889240131</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-a30a2316c4fcb3102b822d652e9ded7035e214c76c1aefdeaac89fef1bbd226c3</originalsourceid><addsrcrecordid>eNo1kEtLw0AUhQdBbK3-A5Es3SSdeyePyVKKVqHgQl2HedzAlCStM5lA_r0B6-rA4eODcxh7AJ4Bh3J7zDxNPdkMOYqlyvJcXrE1VKVMBSCu2G0IR875Qtc3bCWquoBKwpptP2kiT0mYw0i9M8mkgomdG11I3GCjIZvoOXHax9ENTt-x61Z1ge4vuWHfry9fu7f08LF_3z0f0jMCjKkSXKGA0uSt0QI4aoloywKptmQrLgpCyE1VGlDUWlLKyLqlFrS2iKURG_b05z3700-kMDa9C4a6Tg10iqFBKWvMOQhY0McLGvXyQXP2rld-bv5Hil9TkVQb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2889240131</pqid></control><display><type>article</type><title>Severe systemic vasculitis induced by ibrutinib</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fenot, M ; Woaye Hune, P ; Vigouroux, S ; Veyrac, G ; Poiraud, C</creator><creatorcontrib>Fenot, M ; Woaye Hune, P ; Vigouroux, S ; Veyrac, G ; Poiraud, C</creatorcontrib><description>The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib.
A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecrotic lesions on toes and tongue occurred. Skin biopsy found vasculitis of small and medium vessels. Biologic tests were negative. This vasculitis was refractory to systemic corticosteroid therapy and azathioprine. Ibrutinib was stopped on the hypothesis of drug-induced vasculitis. Skin lesions improved after discontinuation of ibrutinib.
The mechanism of action of ibrutinib does not explain the occurrence of vasculitis and an immunoallergic mechanism is suspected.</description><identifier>EISSN: 1768-3122</identifier><identifier>DOI: 10.1016/j.revmed.2023.10.448</identifier><identifier>PMID: 37951781</identifier><language>eng ; fre</language><publisher>France</publisher><subject>Adenine - analogs & derivatives ; Aged ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - complications ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Piperidines ; Protein Kinase Inhibitors - adverse effects ; Systemic Vasculitis ; Vasculitis - chemically induced ; Vasculitis - diagnosis</subject><ispartof>La revue de medecine interne, 2024-01, Vol.45 (1), p.13-16</ispartof><rights>Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37951781$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fenot, M</creatorcontrib><creatorcontrib>Woaye Hune, P</creatorcontrib><creatorcontrib>Vigouroux, S</creatorcontrib><creatorcontrib>Veyrac, G</creatorcontrib><creatorcontrib>Poiraud, C</creatorcontrib><title>Severe systemic vasculitis induced by ibrutinib</title><title>La revue de medecine interne</title><addtitle>Rev Med Interne</addtitle><description>The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib.
A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecrotic lesions on toes and tongue occurred. Skin biopsy found vasculitis of small and medium vessels. Biologic tests were negative. This vasculitis was refractory to systemic corticosteroid therapy and azathioprine. Ibrutinib was stopped on the hypothesis of drug-induced vasculitis. Skin lesions improved after discontinuation of ibrutinib.
The mechanism of action of ibrutinib does not explain the occurrence of vasculitis and an immunoallergic mechanism is suspected.</description><subject>Adenine - analogs & derivatives</subject><subject>Aged</subject><subject>Female</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - complications</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Piperidines</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Systemic Vasculitis</subject><subject>Vasculitis - chemically induced</subject><subject>Vasculitis - diagnosis</subject><issn>1768-3122</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLw0AUhQdBbK3-A5Es3SSdeyePyVKKVqHgQl2HedzAlCStM5lA_r0B6-rA4eODcxh7AJ4Bh3J7zDxNPdkMOYqlyvJcXrE1VKVMBSCu2G0IR875Qtc3bCWquoBKwpptP2kiT0mYw0i9M8mkgomdG11I3GCjIZvoOXHax9ENTt-x61Z1ge4vuWHfry9fu7f08LF_3z0f0jMCjKkSXKGA0uSt0QI4aoloywKptmQrLgpCyE1VGlDUWlLKyLqlFrS2iKURG_b05z3700-kMDa9C4a6Tg10iqFBKWvMOQhY0McLGvXyQXP2rld-bv5Hil9TkVQb</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Fenot, M</creator><creator>Woaye Hune, P</creator><creator>Vigouroux, S</creator><creator>Veyrac, G</creator><creator>Poiraud, C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202401</creationdate><title>Severe systemic vasculitis induced by ibrutinib</title><author>Fenot, M ; Woaye Hune, P ; Vigouroux, S ; Veyrac, G ; Poiraud, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-a30a2316c4fcb3102b822d652e9ded7035e214c76c1aefdeaac89fef1bbd226c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Aged</topic><topic>Female</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - complications</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Piperidines</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Systemic Vasculitis</topic><topic>Vasculitis - chemically induced</topic><topic>Vasculitis - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fenot, M</creatorcontrib><creatorcontrib>Woaye Hune, P</creatorcontrib><creatorcontrib>Vigouroux, S</creatorcontrib><creatorcontrib>Veyrac, G</creatorcontrib><creatorcontrib>Poiraud, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La revue de medecine interne</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fenot, M</au><au>Woaye Hune, P</au><au>Vigouroux, S</au><au>Veyrac, G</au><au>Poiraud, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe systemic vasculitis induced by ibrutinib</atitle><jtitle>La revue de medecine interne</jtitle><addtitle>Rev Med Interne</addtitle><date>2024-01</date><risdate>2024</risdate><volume>45</volume><issue>1</issue><spage>13</spage><epage>16</epage><pages>13-16</pages><eissn>1768-3122</eissn><abstract>The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib.
A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecrotic lesions on toes and tongue occurred. Skin biopsy found vasculitis of small and medium vessels. Biologic tests were negative. This vasculitis was refractory to systemic corticosteroid therapy and azathioprine. Ibrutinib was stopped on the hypothesis of drug-induced vasculitis. Skin lesions improved after discontinuation of ibrutinib.
The mechanism of action of ibrutinib does not explain the occurrence of vasculitis and an immunoallergic mechanism is suspected.</abstract><cop>France</cop><pmid>37951781</pmid><doi>10.1016/j.revmed.2023.10.448</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1768-3122 |
| ispartof | La revue de medecine interne, 2024-01, Vol.45 (1), p.13-16 |
| issn | 1768-3122 |
| language | eng ; fre |
| recordid | cdi_proquest_miscellaneous_2889240131 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenine - analogs & derivatives Aged Female Humans Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Piperidines Protein Kinase Inhibitors - adverse effects Systemic Vasculitis Vasculitis - chemically induced Vasculitis - diagnosis |
| title | Severe systemic vasculitis induced by ibrutinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A41%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20systemic%20vasculitis%20induced%20by%20ibrutinib&rft.jtitle=La%20revue%20de%20medecine%20interne&rft.au=Fenot,%20M&rft.date=2024-01&rft.volume=45&rft.issue=1&rft.spage=13&rft.epage=16&rft.pages=13-16&rft.eissn=1768-3122&rft_id=info:doi/10.1016/j.revmed.2023.10.448&rft_dat=%3Cproquest_pubme%3E2889240131%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2889240131&rft_id=info:pmid/37951781&rfr_iscdi=true |